Amphastar Pharmaceuticals (NASDAQ:AMPH) Trading Up 3.3%

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPHGet Rating)’s share price was up 3.3% during mid-day trading on Tuesday . The stock traded as high as $39.70 and last traded at $39.70. Approximately 1,242 shares traded hands during mid-day trading, a decline of 100% from the average daily volume of 425,549 shares. The stock had previously closed at $38.43.

Several research analysts have recently issued reports on AMPH shares. Northland Securities raised their target price on shares of Amphastar Pharmaceuticals from $33.00 to $43.00 in a report on Monday, April 11th. Wells Fargo & Company raised their target price on shares of Amphastar Pharmaceuticals from $23.00 to $32.00 and gave the stock an “equal weight” rating in a report on Tuesday, March 15th. Zacks Investment Research cut shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, January 19th. StockNews.com started coverage on shares of Amphastar Pharmaceuticals in a report on Thursday, March 31st. They issued a “buy” rating on the stock. Finally, Piper Sandler raised their target price on shares of Amphastar Pharmaceuticals from $28.00 to $35.00 and gave the stock an “overweight” rating in a report on Friday, March 11th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, Amphastar Pharmaceuticals presently has an average rating of “Hold” and an average price target of $33.50.

The company has a market cap of $1.89 billion, a price-to-earnings ratio of 30.99 and a beta of 0.69. The business’s fifty day simple moving average is $33.02. The company has a current ratio of 3.06, a quick ratio of 2.17 and a debt-to-equity ratio of 0.17.

Amphastar Pharmaceuticals (NASDAQ:AMPHGet Rating) last released its quarterly earnings results on Thursday, March 10th. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.04. The business had revenue of $120.89 million for the quarter, compared to analysts’ expectations of $111.38 million. Amphastar Pharmaceuticals had a net margin of 14.19% and a return on equity of 15.16%. During the same quarter in the previous year, the business posted $0.16 earnings per share. Equities analysts predict that Amphastar Pharmaceuticals, Inc. will post 1.62 earnings per share for the current fiscal year.

In other Amphastar Pharmaceuticals news, EVP Rong Zhou sold 7,000 shares of the firm’s stock in a transaction on Tuesday, February 8th. The stock was sold at an average price of $26.77, for a total transaction of $187,390.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO William J. Peters sold 10,000 shares of the firm’s stock in a transaction on Tuesday, February 8th. The shares were sold at an average price of $26.95, for a total value of $269,500.00. The disclosure for this sale can be found here. Insiders have sold 36,400 shares of company stock valued at $1,110,244 in the last three months. Insiders own 28.40% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of AMPH. First Quadrant L P CA purchased a new position in shares of Amphastar Pharmaceuticals in the 4th quarter worth about $36,000. Allworth Financial LP purchased a new position in shares of Amphastar Pharmaceuticals in the 4th quarter worth about $42,000. Lazard Asset Management LLC purchased a new position in shares of Amphastar Pharmaceuticals in the 4th quarter worth about $42,000. Advisor Group Holdings Inc. raised its position in shares of Amphastar Pharmaceuticals by 314.2% in the 4th quarter. Advisor Group Holdings Inc. now owns 2,311 shares of the company’s stock worth $54,000 after purchasing an additional 1,753 shares during the last quarter. Finally, Royal Bank of Canada raised its position in shares of Amphastar Pharmaceuticals by 253.4% in the 2nd quarter. Royal Bank of Canada now owns 3,534 shares of the company’s stock worth $71,000 after purchasing an additional 2,534 shares during the last quarter. 59.69% of the stock is owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Company Profile (NASDAQ:AMPH)

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API.

Recommended Stories

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.